MRVI Q2 2021 Earnings — Maravai LifeSciences Holdings, Inc. Revenue & Financial Results | Market Cap Arena

MRVIMaravai LifeSciences Holdings, Inc.

$999M

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$218M+364.3% YoY

Gross Profit

$180M82.6% margin

Operating Income

$154M70.5% margin

Net Income

$49M22.6% margin

EPS (Diluted)

$0.44

QoQ Revenue Growth

+46.9%

Cash Flow

Operating Cash Flow

$166M

Free Cash Flow

$161M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$1.3B

Stockholders' Equity

$194M

Cash & Equivalents

$375M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$218M	$47M	+364.3%
Gross Profit	$180M	$26M	+600.0%
Operating Income	$154M	$8M	+1790.8%
Net Income	$49M	$207,000	+23640.6%

Revenue Segments

Nucleic Acid Production Segment

$193M88%

Biologics Safety Testing Segment

$18M8%

Protein Detection Segment

$7M3%